相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Nivolumab (NIVO)+5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials
Claire Gallois et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC)
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan
Masahito Kotaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405
Marla Lipsyc-Sharf et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Marwan G. Fakih et al.
LANCET ONCOLOGY (2022)
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
K. Yamazaki et al.
ANNALS OF ONCOLOGY (2021)
KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer
Kai-Keen Shiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study.
Valerie Boige et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
John H. Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The efficacy and safety of anlotinib in refractory colorectal cancer: A double-blinded, placebo controlled, randomized phase III ALTER0703 trial.
Yihebali Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
Francois Quenet et al.
LANCET ONCOLOGY (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer
Arvind Dasari et al.
FUTURE ONCOLOGY (2021)
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial
Jeffrey A. Meyerhardt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Jennifer S. Lin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
Karina W. Davidson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
Thierry Andre et al.
LANCET ONCOLOGY (2021)
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena et al.
LANCET ONCOLOGY (2021)
Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
T. Andre et al.
ANNALS OF ONCOLOGY (2021)
Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status
V. Boige et al.
ANNALS OF ONCOLOGY (2021)
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial
Richard A. Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database
Zhaohui Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)
Yihebali Chi et al.
ONCOLOGIST (2021)
Colorectal cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer A Subgroup Analysis of the TOSCA Randomized Clinical Trial
Fausto Petrelli et al.
JAMA ONCOLOGY (2020)
Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer
Zhengyi Zhao et al.
JAMA ONCOLOGY (2020)
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
Federica Tosi et al.
CLINICAL COLORECTAL CANCER (2020)
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
S. Siena et al.
ANNALS OF ONCOLOGY (2018)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prevalence of RAS and BRAF mutations in metastatic colorectal cancer (mCRC) patients by tumor location.
Lauren C. Bylsma et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Colorectal cancer: a disease of the young?
[Anonymous]
LANCET ONCOLOGY (2017)
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants
Hongmei Nan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H. J. Simkens et al.
LANCET (2015)
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
Susanna Hegewisch-Becker et al.
LANCET ONCOLOGY (2015)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)